Mankind Pharma (MANKIND) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 revenue grew 12.2% year-on-year to ₹2,893 crore, with adjusted EBITDA margin at 25.2% and PAT margin at 19%.

• BSV Limited acquisition announced for ₹13,630 crore, expanding into super specialty and high entry barrier products, expected to be EPS accretive from the second full year.

• Consumer healthcare business saw sequential revenue growth of 32%, with key brands maintaining leadership.

• Export revenues grew 62% year-on-year, driven by base business and new launches.

• Maintained #2 rank by volume in IPM with a 6.1% market share in Q1 FY25.

Financial highlights

• Revenue from operations rose to ₹2,893.42 crore, up 12.2% year-on-year.

• Gross margin improved to 71.9% (up 3.7% year-on-year), mainly from price increases and favorable sales mix.

• Adjusted EBITDA at ₹728 crore, margin at 25.2%; reported EBITDA margin at 23.7% due to one-time M&A costs.

• Profit after tax increased to ₹543.07 crore; diluted EPS at ₹13.39.

• Net cash position as of June 30, 2024, ranged from ₹1,727 crore to ₹3,747 crore.

Outlook and guidance

• EBITDA margin guidance retained at 25%-26% for FY25.

• BSV acquisition expected to deliver double-digit top-line growth and 30%+ EBITDA margin; synergy benefits of ₹50–100 crore over 12–24 months.

• R&D expenses expected to remain around 2% of revenue.

• CapEx for FY25 projected at 4%-5% of revenue.

• Export growth expected to continue at mid-teen rates.